People participate in dermatology research for several reasons. Some hope to get the most advanced treatments available for dermatological conditions or illnesses. Others participate because they want to assist with research to develop better ways to help and treat people.
All trial and study patients are identified by the consultant and research nurses. Once research participants are identified they are then approached by the research team and given information regarding the trial or study. If the patient would like to take part, informed consent is obtained. The research team is then responsible for the patient’s experience. Ensuring safety and best interests are paramount.
British Association of Dermatologists Biologic and Immunomodulators Register. They are a UK and Eire observational study seeking to assess the long-term safety of biologic treatments for psoriasis.
Biomarkers and Stratification to Optimise outcomes in Psoriasis (BSTOP) is a study which seeks to identify and characterise biomarkers of response to systemic and biologic treatments for psoriasis. The aim of BSTOP is to identify markers that will enable doctors to give the right medicine to the right patient at the right time.
Pustular psoriasis is a rare but very severe skin disease. Current therapies have limited efficacy and may cause significant side effects, partly because the cause of the disease is not fully understood. With this study, we seek to identify the genetic defects that cause pustular psoriasis and understand how they alter immune responses and result in disease.
The UK-Irish Atopic eczema Systemic Therapy Register (A-STAR). The purpose of the research study is to collect information from adult patients with eczema, starting certain treatments, such as ciclosporin, methotrexate, azathioprine, or novel treatments, such as biologics and so-called ‘small molecules’ As eczema is often a long-term condition, it is important to establish how well these medicines work with regard to improvement in disease severity, quality of life and also safety, especially when these medicines are used for longer periods of time.
A Phase 2a/b, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL 716 in Reducing Pruritus in Subjects with Prurigo Nodularis.
Please feel free to contact the team for further information about current and future dermatology research at Broadgreen Hospital.
You can contact our Research Nurses Sarah Aldwinckle or Jean Roberts on 0151 282 6958.